Ausgabe 4/2019
Inhalt (12 Artikel)
Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient
Zhe Yang, Jinqi Yang, Yedan Chen, Yang W. Shao, Xing Wang
The Role of Checkpoint Inhibitors in Glioblastoma
Kunal Desai, Anne Hubben, Manmeet Ahluwalia
Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis
Jisun Park, Jinhyun Cho, Joo Han Lim, Moon Hee Lee, Jinchul Kim
Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
Michael Moran, Dana Nickens, Katherine Adcock, Meg Bennetts, Arial Desscan, Natalie Charnley, Kate Fife
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
Anna W. Chalmers, Shiven Patel, Ken Boucher, Laura Cannon, Michelle Esplin, Julie Luckart, Natalie Graves, Terry Van Duren, Wallace Akerley
Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma
Changhui Li, Bo Zhang, Jindong Guo, Fang Hu, Wei Nie, Xiaoxuan Zheng, Lixin Wang, Yuqing Lou, Yinchen Shen, Baohui Han, Xueyan Zhang
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane
Annelieke E. C. A. B. Willemsen, Jolien Tol, Nielka P. van Erp, Marianne A. Jonker, Maaike de Boer, Bob Meek, Paul C. de Jong, Coline van Moorsel, Winald R. Gerritsen, Jan C. Grutters, Carla M. L. van Herpen
Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
Hiroki Ishihara, Hidekazu Tachibana, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
Y. Louise Wan, Puja Sapra, James Bolton, Jia Xin Chua, Lindy G. Durrant, Peter L. Stern
A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma
Fares Nigim, Juri Kiyokawa, Alessandra Gurtner, Yoichiro Kawamura, Lingyang Hua, Ekkehard M. Kasper, Priscilla K. Brastianos, Daniel P. Cahill, Samuel D. Rabkin, Robert L. Martuza, W. Shawn Carbonell, Hiroaki Wakimoto
Correction to: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma
Changhui Li, Bo Zhang, Jindong Guo, Fang Hu, Wei Nie, Xiaoxuan Zheng, Lixin Wang, Yuqing Lou, Yinchen Shen, Baohui Han, Xueyan Zhang